JP2016511755A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016511755A5 JP2016511755A5 JP2015555829A JP2015555829A JP2016511755A5 JP 2016511755 A5 JP2016511755 A5 JP 2016511755A5 JP 2015555829 A JP2015555829 A JP 2015555829A JP 2015555829 A JP2015555829 A JP 2015555829A JP 2016511755 A5 JP2016511755 A5 JP 2016511755A5
- Authority
- JP
- Japan
- Prior art keywords
- factor
- pharmaceutical composition
- variant
- seconds
- inhibitor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361759332P | 2013-01-31 | 2013-01-31 | |
| US61/759,332 | 2013-01-31 | ||
| PCT/IB2014/058494 WO2014118677A1 (en) | 2013-01-31 | 2014-01-23 | Compositions and methods for counteracting factor xa inhibition |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190856A Division JP2019077677A (ja) | 2013-01-31 | 2018-10-09 | 第Ｘａ因子の阻害を中和するための組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2016511755A JP2016511755A (ja) | 2016-04-21 |
| JP2016511755A5 true JP2016511755A5 (enExample) | 2017-03-30 |
| JP6437458B2 JP6437458B2 (ja) | 2018-12-12 |
Family
ID=50114451
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015555829A Expired - Fee Related JP6437458B2 (ja) | 2013-01-31 | 2014-01-23 | 第Ｘａ因子の阻害を中和するための組成物および方法 |
| JP2018190856A Withdrawn JP2019077677A (ja) | 2013-01-31 | 2018-10-09 | 第Ｘａ因子の阻害を中和するための組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018190856A Withdrawn JP2019077677A (ja) | 2013-01-31 | 2018-10-09 | 第Ｘａ因子の阻害を中和するための組成物および方法 |
Country Status (12)
| Country | Link |
|---|---|
| US (3) | US20150343034A1 (enExample) |
| EP (1) | EP2950813B1 (enExample) |
| JP (2) | JP6437458B2 (enExample) |
| KR (1) | KR20150103205A (enExample) |
| CN (1) | CN104994868A (enExample) |
| AU (1) | AU2014210830A1 (enExample) |
| CA (1) | CA2897672A1 (enExample) |
| ES (1) | ES2761730T3 (enExample) |
| HK (1) | HK1215196A1 (enExample) |
| IL (1) | IL240147A0 (enExample) |
| MX (1) | MX2015008813A (enExample) |
| WO (1) | WO2014118677A1 (enExample) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2761730T3 (es) | 2013-01-31 | 2020-05-20 | Pfizer | Composiciones y procedimientos para contrarrestar la inhibición del factor Xa |
| KR101988705B1 (ko) | 2013-09-24 | 2019-06-12 | 화이자 인코포레이티드 | 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 |
| JP6629744B2 (ja) * | 2013-11-01 | 2020-01-15 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 第Ｘａ因子の半減期を延ばす組成物および方法 |
| AU2015208819B2 (en) * | 2014-01-24 | 2020-01-23 | Pfizer Inc. | Compositions and methods for treating intracerebral hemorrhage |
| WO2015183085A1 (en) | 2014-05-26 | 2015-12-03 | Academisch Ziekenhuis Leiden | Prohemostatic proteins for the treatment of bleeding |
| ES2907190T3 (es) | 2014-07-31 | 2022-04-22 | Haemonetics Corp | Detección de la reversión de un anticoagulante mediante pruebas de coagulación por ecarina y factor Xa |
| US10676731B2 (en) | 2014-08-19 | 2020-06-09 | The Children's Hospital Of Philadelphia | Compositions and methods for modulating factor IX function |
| CN105440127B (zh) * | 2015-12-30 | 2018-10-16 | 上海莱士血液制品股份有限公司 | 一种以人血浆Cohn组分III为原料的FEIBA的制备方法 |
| TW201802121A (zh) | 2016-05-25 | 2018-01-16 | 諾華公司 | 抗因子XI/XIa抗體之逆轉結合劑及其用途 |
| AU2017383232B2 (en) | 2016-12-23 | 2024-09-12 | Novartis Ag | Factor XI antibodies and methods of use |
| JP7641903B2 (ja) * | 2019-02-07 | 2025-03-07 | アレクシオン ファーマシューティカルズ， インコーポレイテッド | 頭蓋内出血の治療方法及び効果の評価方法 |
| CN114681597A (zh) * | 2022-03-11 | 2022-07-01 | 兆科药业（合肥）有限公司 | 蝰蛇蛇毒血凝酶在制备用于逆转凝血因子Xa抑制剂的抗凝作用的药物中的应用 |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5597799A (en) | 1990-09-04 | 1997-01-28 | Cor Therapeutics, Inc. | Recombinant agents affecting thrombosis |
| US6369080B2 (en) | 1996-10-11 | 2002-04-09 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| US6262047B1 (en) | 1996-10-11 | 2001-07-17 | Cor Therapeutics, Inc. | Selective factor Xa inhibitors |
| AT405516B (de) | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-analoge mit modifizierter proteasespaltstelle |
| AT405517B (de) * | 1997-02-27 | 1999-09-27 | Immuno Ag | Faktor x-deletionsmutanten und analoge davon |
| US6133256A (en) | 1997-04-14 | 2000-10-17 | Cor Therapeutics Inc | Selective factor Xa inhibitors |
| GB9908838D0 (en) | 1998-09-11 | 1999-06-16 | Univ London | Fibroblast inhibitor |
| AT410216B (de) | 1999-08-10 | 2003-03-25 | Baxter Ag | Faktor x-analogon mit verbesserter aktivierbarkeit |
| US20040102388A1 (en) | 2000-03-22 | 2004-05-27 | High Katherine A. | Modified blood clotting factors and methods of use |
| US6905683B2 (en) | 2000-05-03 | 2005-06-14 | Novo Nordisk Healthcare A/G | Human coagulation factor VII variants |
| FR2831170B1 (fr) | 2001-10-19 | 2004-03-19 | Inst Nat Sante Rech Med | Proteines c modifiees activables directement par la thrombine |
| FR2841904B1 (fr) | 2002-07-03 | 2004-08-20 | Inst Nat Sante Rech Med | Analogues de facteurs x clivables par la thrombine |
| EP1728798A1 (en) | 2005-06-01 | 2006-12-06 | ZLB Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| DE102005028018A1 (de) * | 2005-06-16 | 2006-12-21 | Dade Behring Marburg Gmbh | Verfahren zur Standardisierung von Gerinnungstesten |
| MX2008006313A (es) * | 2005-11-15 | 2008-11-06 | Philadelphia Children Hospital | Metodos y composiciones para modular la hemostasia. |
| EP1820508A1 (en) | 2006-02-21 | 2007-08-22 | CSL Behring GmbH | Coagulation factor X polypeptides with modified activation properties |
| EP1867660A1 (en) | 2006-06-14 | 2007-12-19 | CSL Behring GmbH | Proteolytically cleavable fusion protein comprising a blood coagulation factor |
| PT3078743T (pt) * | 2007-09-28 | 2020-07-15 | Portola Pharm Inc | Antídotos para inibidores do fator xa e métodos de utilização dos mesmos |
| US20100297257A1 (en) | 2007-11-09 | 2010-11-25 | National Institutes Of Health (Nih), U.S. Dept. Of Health And Human Services (Dhhs) | Anticoagulant antagonist and hemophillia procoagulant |
| US8455439B2 (en) | 2008-11-14 | 2013-06-04 | Portola Pharmaceuticals, Inc. | Antidotes for factor Xa inhibitors and methods of using the same in combination with blood coagulating agents |
| US8436144B2 (en) | 2008-12-19 | 2013-05-07 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Serine protease derivatives and uses in the prevention or the treatment of blood coagulation disorders |
| EP3604510B1 (en) | 2009-03-30 | 2025-03-26 | Alexion Pharmaceuticals, Inc. | Antidotes for factor xa inhibitors and methods of using the same |
| WO2011008885A1 (en) * | 2009-07-15 | 2011-01-20 | Portola Pharmaceuticals, Inc. | Unit dose formulation of antidotes for factor xa inhibitors and methods of using the same |
| GB2485590A (en) | 2010-11-22 | 2012-05-23 | Univ Ruprecht Karis Heidelberg | Method for detecting at least one direct factor Xa inhibitors |
| FR2972114B1 (fr) | 2011-03-01 | 2013-03-15 | Univ Grenoble 1 | Un nouveau leurre moleculaire procoagulant pour le traitement des hemophiles a ou b avec ou sans inhibiteur |
| EP2760887B1 (en) | 2011-09-30 | 2024-10-23 | The Children's Hospital of Philadelphia | Compositions and methods for modulating hemostasis |
| WO2013123248A1 (en) | 2012-02-16 | 2013-08-22 | Portola Pharmaceuticals, Inc. | MODULATION OF FACTOR Xa INHIBITOR MEDIATED BLOOD LOSS BY PARTIAL AND TRANSIENT ADMINISTRATION OF ANTIDOTE |
| FR3000895B1 (fr) | 2013-01-11 | 2017-02-24 | Laboratoire Francais Du Fractionnement Et Des Biotechnologies Sa | Utilisation d'antidotes d'inhibiteurs de la coagulation indiques dans la prevention ou le traitement de pathologies thromboemboliques |
| ES2761730T3 (es) | 2013-01-31 | 2020-05-20 | Pfizer | Composiciones y procedimientos para contrarrestar la inhibición del factor Xa |
| KR101988705B1 (ko) * | 2013-09-24 | 2019-06-12 | 화이자 인코포레이티드 | 재조합 인간 응고 인자 Xa 단백질의 이질적 집단을 포함하는 조성물 |
| JP6629744B2 (ja) | 2013-11-01 | 2020-01-15 | ザ・チルドレンズ・ホスピタル・オブ・フィラデルフィアＴｈｅ Ｃｈｉｌｄｒｅｎ’Ｓ Ｈｏｓｐｉｔａｌ Ｏｆ Ｐｈｉｌａｄｅｌｐｈｉａ | 第Ｘａ因子の半減期を延ばす組成物および方法 |
| AU2015208819B2 (en) * | 2014-01-24 | 2020-01-23 | Pfizer Inc. | Compositions and methods for treating intracerebral hemorrhage |
-
2014
- 2014-01-23 ES ES14704915T patent/ES2761730T3/es active Active
- 2014-01-23 MX MX2015008813A patent/MX2015008813A/es unknown
- 2014-01-23 CA CA2897672A patent/CA2897672A1/en not_active Abandoned
- 2014-01-23 US US14/759,520 patent/US20150343034A1/en not_active Abandoned
- 2014-01-23 JP JP2015555829A patent/JP6437458B2/ja not_active Expired - Fee Related
- 2014-01-23 EP EP14704915.9A patent/EP2950813B1/en active Active
- 2014-01-23 KR KR1020157020717A patent/KR20150103205A/ko not_active Withdrawn
- 2014-01-23 HK HK16103318.1A patent/HK1215196A1/zh unknown
- 2014-01-23 AU AU2014210830A patent/AU2014210830A1/en not_active Abandoned
- 2014-01-23 CN CN201480006917.0A patent/CN104994868A/zh active Pending
- 2014-01-23 WO PCT/IB2014/058494 patent/WO2014118677A1/en not_active Ceased
-
2015
- 2015-07-26 IL IL240147A patent/IL240147A0/en unknown
-
2018
- 2018-01-17 US US15/873,416 patent/US10588950B2/en active Active
- 2018-10-09 JP JP2018190856A patent/JP2019077677A/ja not_active Withdrawn
-
2020
- 2020-03-16 US US16/820,687 patent/US20210000930A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016511755A5 (enExample) | ||
| JP2015517488A5 (enExample) | ||
| CY1121150T1 (el) | Νευροδραστικα 19-αλκοξυ-17-υποκατεστημενα στεροειδη, χρησιμα σε μεθοδους θεραπειας | |
| JP2016540738A5 (enExample) | ||
| EA201691375A1 (ru) | (2s)-n-[(1s)-1-циано-2-фенилэтил]-1,4-оксазепан-2-карбоксамиды в качестве ингибиторов дипептидилпептидазы i | |
| HK1247823A1 (zh) | 骨质疏松的治疗 | |
| EA201490377A1 (ru) | Лечение рассеянного склероза комбинацией лаквинимода и глатирамера ацетата | |
| JP2015518818A5 (enExample) | ||
| BR112013022217A8 (pt) | composição farmacêutica, método de tratamento preventivo de uma síndrome hemorrágica em um paciente com hemofilia a ou b e método de tratamento de um acidente hemorrágico em um paciente com hemofilia a ou b | |
| JP2018509388A5 (enExample) | ||
| JP2013533867A5 (enExample) | ||
| JP2013515022A (ja) | 相乗的抗ウイルス組成物及びその使用 | |
| JP2014529606A5 (enExample) | ||
| WO2015017423A3 (en) | Stabilized modified release folic acid derivative composition, its therapeutic use and methods of manufacture | |
| JP2015512420A5 (enExample) | ||
| NZ631105A (en) | Methods for treating or preventing influenza virus infection by administering a serine protease inhibitor | |
| HRP20180316T1 (hr) | Izolirani čvrsti oblik anamorelin monohidroklorida s niskim molarnim odnosom klorida: anamolerina i niskim sadržajem rezidualnog organskog otapala | |
| JP2018505901A5 (enExample) | ||
| RU2017114678A (ru) | Перорально распадающаяся твердая фармацевтическая единица дозирования, содержащая контролирующее родовую деятельность вещество | |
| HRP20241276T1 (hr) | Profilaktičko i/ili terapeutsko sredstvo za demenciju | |
| JP2019513765A5 (enExample) | ||
| PE20061126A1 (es) | Formas de dosificacion oral solidas que contienen una dosis baja de estradiol | |
| JP2014177492A5 (enExample) | ||
| EA201591218A1 (ru) | Способы и композиции для введения оксибутинина | |
| WO2015066606A3 (en) | Compositions and methods for increasing the half-life of factor xa |